United States: False Claims Act's "Rigorous" Materiality Standard Enforced By Second Circuit

The Situation: A decision by the U.S. Court of Appeals for the Second Circuit reinforces the growing body of case law regarding the strict materiality requirements of the False Claims Act.

The Result: Coyne v. Amgen is evidence of the impact the Supreme Court's decision in Universal Health Services, Inc. v. Escobar has had on the FCA's materiality standards.

Looking Ahead: Applying Escobar's "rigorous" standard on a motion to dismiss, Coyne shows that materiality must be alleged with some detail in FCA cases.

The U.S. Court of Appeals for the Second Circuit, in a recent decision in Coyne v. Amgen, Inc., 17-1522-cv, added to the growing body of case law enforcing the False Claims Act's ("FCA") materiality requirement strictly after the Supreme Court's landmark decision in Universal Health Services, Inc. v. Escobar, 136 S. Ct. 1989 (2016). Reviewing the district court's grant of a motion to dismiss under the FCA's public disclosure bar, the Second Circuit instead affirmed on alternative grounds, under Escobar's materiality standard. Though a nonprecedential ruling, Coyne shows the enormous impact that Escobar has had on FCA litigation—and, in particular, how courts are following the Supreme Court's guidance to enforce materiality strictly even on the pleadings, as happened in Coyne.

Coyne concerned the drug Epogen, manufactured by defendant Amgen, Inc. ("Amgen") and approved by the Food and Drug Administration ("FDA") to treat anemia in patients with chronic kidney disease. Relator Dr. Daniel Coyne—a former paid speaker for Amgen—alleged that Epogen's packaging was misleading. Specifically, he alleged that Epogen's packaging set forth the drug's FDA-approved usage to treat chronic kidney disease by raising hemoglobin levels to a target of 10-12 grams per deciliter (g/dL) but did not suggest any differences within that range, even though Amgen knew that taking Epogen beyond the 11 g/dL level would not confer any discernable quality of life benefits. Coyne alleged that Amgen learned this from a clinical trial of patients who maintained hemoglobin levels of 9-11 g/dL ("low arm") and 13-15 g/dL ("high arm"); in 1996, after patients in the study's high arm experienced an increase in adverse events, Amgen halted the study and reported the results to the FDA. Coyne alleged that Amgen continued to market Epogen as approved for usage up to 12 g/dL without noting the drug's limitations in the label.

According to Coyne's complaint, between 1996 and 2011, Amgen's purportedly misleading packaging for Epogen caused the submission of false claims to the Centers for Medicare and Medicaid Services ("CMS") that implicitly certified compliance with CMS's requirement that prescribed medication be "reasonable and necessary" under 42 U.S.C. § 1395y(a)(1)(A). After the district court granted Amgen's motion to dismiss on public-disclosure grounds, Coyne appealed.

Instead of addressing the public-disclosure arguments, the Second Circuit affirmed on alternate grounds of materiality. Emphasizing that "the complaint must present concrete allegations from which the court may draw the reasonable inference that the misrepresentations on Epogen's packaging and marketing materials caused the Government to make the reimbursement decision," the court explained that Coyne's complaint merely "relies on a conclusory assertion that Amgen's failure to disclose the [above] study to CMS was material to, or in effect caused, payment" (emphasis added). This was not enough.

Moreover, the court found that the concrete facts only belied Coyne's claim: because the 10-12 g/dL range was FDA-approved, prescriptions consistent with that use were "presumptively 'reasonable and necessary' for purposes of CMS reimbursement." In addition, the court pointed to new labeling for Epogen in 2007—which was not cited in the complaint, but was publicly available—that added the very information that Coyne contended had been previously missing. The court concluded that, "armed with this information, CMS did not alter its reimbursement practices with respect to Epogen or exercise any independent discretion from the presumption of FDA approval." The government's practices thus showed that "any concealment of the [study's] data from CMS was immaterial to its payment decisions."

Coyne is the latest evidence that courts are taking seriously the Supreme Court's statements in Escobar that the FCA's materiality requirement is "rigorous," that it is not "sufficient for a finding of materiality that the Government would have the option to decline to pay if it knew of the defendant's noncompliance," and that this standard is not too fact-sensitive to be enforced on a motion to dismiss. Indeed, Coyne demonstrates that courts will consider publicly available materials outside the record—even on a motion to dismiss—when evaluating materiality. Applying Escobar's "rigorous" standard, Coyne shows that materiality must be alleged with some detail and bolsters the growing consensus that the government's decision to continue paying claims with knowledge of the misrepresentation precludes a finding of materiality.


1. The Coyne decision is further illustration that courts are taking seriously the Supreme Court's statements in Escobar that the FCA's materiality requirement is "rigorous."

2. Coyne also demonstrates that courts will consider publicly available materials outside the record when evaluating materiality.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Sign Up
Gain free access to lawyers expertise from more than 250 countries.
Email Address
Company Name
Confirm Password
Mondaq Newsalert
Select Topics
Select Regions
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions